medigraphic.com
Boletín Médico del Hospital Infantil de México

2011, Number 1

<< Back Next >>

Bol Med Hosp Infant Mex 2011; 68 (1)

A scoring system to predict superinfections in high-risk febrile neutropenic children with cancer

Paganini H, Caccavo J, Aguirre C, Gómez S, Zubizarreta P

Language: English
References: 28
Page: 40-47
PDF size: 282.08 Kb.


Text Extraction

Background. No scoring system has been published to date to assess the risk of superinfections (SI) for high-risk children with febrile neutropenia (HRFN).
Methods. SI diagnoses during or 1 week after initiating antibiotic therapy in HRFN children were evaluated. Eight hundred and forty-nine episodes of febrile neutropenia (FN) were included in a prospective study to evaluate a scoring system designed to identify SI.
Results. In the derivation set (566 episodes), 17% had SI. A multivariate analysis identified the following significant SI-related risk factors: acute lymphoblastic leukemia-acute myeloid leukemia (ALL-AML, OR, 1.87; 95% CI, 1.13-3.10), central venous catheter (OR, 2.11; 95% CI, 1.23-3.62), and febrile episode occurring within 10 days after chemotherapy (OR, 1.86; 95% CI, 1.09-3.15). A SI scoring system could be built: 1 point for ALL-AML, 1 point for the presence of a central venous catheter, and 1 point for the febrile episode occurring within 10 days after chemotherapy. If patients collected 3 points, then their risk of SI was 25.8%. With 2 points the risk was 16.7%, and with one minimum score of 1 point, their risk was 10.9%. The sensitivity to predict SS was 100% and its negative predictive value (NPV) was 100%. In the validation set (283 episodes), 49 (17%) children had SI. For children with scores › 0, the scoring system yielded a sensitivity of 100%, and a NPV of 100% for predicting SI.
Conclusions. The use of a SI score for HRFN patients was statistically validated by these results. A better initial predictive approach may allow improved therapeutic decisions for these children.


REFERENCES

  1. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002;39:77-85.

  2. Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al. Epidemiology and risk factors for grampositive coccal infections in neutropenia: toward a more targeted antibiotic stratategy. Clin Infect Dis 2003;36:149-158.

  3. Paesmans M. Risk factors assessment in febrile neutropenia. Int J Antmicrob Agents 2000;16:107-111.

  4. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996;14:919-924.

  5. Paganini H, Bologna R, Debbag R, Casimir L, Gómez S, Rosanova M, et al. Fever and neutropenia in children with cancer in one pediatric hospital in Argentina. Pediatr Hematol Oncol 1998;15:405-413.

  6. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Inter Med 1988;148:2561-2568.

  7. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.

  8. Klastersky J, Paesmans M, Rubenstein RB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.

  9. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Fernández C, et al. Criteria of low risk of mortality in children with neutropenia and fever during cancer chemotherapy. Medicina (B Aires) 2001;61:63-66.

  10. Hughes WT, Armstrong D, Bodey G, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.

  11. Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-165.

  12. Akova M, Paesmans M, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 2005;40:239-245.

  13. Nucci M, Spector N, Bueno AP, Solza C, Perecmanis T, Bacha PC, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997;24:575-579.

  14. Feld R, Goodman PJ, Higgins B, De Pauw BE, Deresinski S, Donnelly JP, et al. Prognostic factors for the development of superinfections in febrile neutropenic cancer patients (abstract 1695). 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 11-14 October 1992, Anaheim, CA.

  15. Serra P, Santini C, Venditti M, Mandelli F, Martino D. Superinfections during antimicrobial treatment with betalactamaminoglycoside combinations in neutropenic patients with hematologic malignancies. Infection 1985;13(suppl 1):S115-122.

  16. Guiget M, Blot F, Escudier B, Antoun S, Leclercq B, Nitenberg G. Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: which is the best predictor? Do multiple assessment times improve the predictive value? Crit Care Med 1998;26:488-493.

  17. Paganini H, Aguirre C, Puppa G, Garbini C, Javier RG, Ensinck G, et al. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer 2007;109:2572-2579.

  18. Sáez-Llorens X, McCracken GH Jr. Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993;123:497-508.

  19. Lacy CF, Armstrong LL, Godman MP, Lance LL. Drug Information Handbook. Hudson, OH: Lexi-Comp; 1999.

  20. Paganini H, Sarkis CM, De Martino MG, Zubizarreta PA, Casimir L, Fernández C, et al. Oral administration of cefixime to lower risk of febrile neutropenic children with cancer. Cancer 2000;88:2848-2852.

  21. Paganini H, Rodriguez-Brischcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. A randomized controlled trial. Cancer 2001;91:1563-1567.

  22. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126-134.

  23. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515-521.

  24. Paganini H, Gomez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease. A single-center, randomized, controlled trial in Argentina. Cancer 2003;97:1775-1780.

  25. Paganini H, Rodriguez-Brieshcke T, Casimir L, Seu S. Risk factors for nosocomial bacterial infection in children: a casecontrol study. Medicina (B Aires) 1999;59:43-48.

  26. Santolaya ME, Alvarez AM, Becker A, Cofré J, Enríquez N, O’Ryan M, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001;19:3415-3421.

  27. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197-208.

  28. Wenzel RP. The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? Int J Epidemiol 1988;17:225-227.




2020     |     www.medigraphic.com